Leadpram-LS Tablet is a combination pharmaceutical formulation containing Clonazepam 0.25 mg and Escitalopram Oxalate 5 mg, indicated for the management of anxiety disorders, panic attacks, and depressive episodes associated with anxiety. Clonazepam, a benzodiazepine derivative, exerts its therapeutic effect by enhancing the activity of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the central nervous system, thereby producing anxiolytic, anticonvulsant, and muscle relaxant properties. Escitalopram Oxalate, a selective serotonin reuptake inhibitor (SSRI), increases serotonin levels in the synaptic cleft by inhibiting its reuptake, contributing to improved mood and reduced anxiety symptoms. The synergistic action of these two agents provides both rapid anxiolytic effects and sustained antidepressant benefits, making Leadpram-LS suitable for patients requiring comprehensive management of anxiety and depressive symptoms. It is essential to use this medication under strict medical supervision due to potential side effects such as drowsiness, dizziness, gastrointestinal disturbances, and the risk of dependence associated with clonazepam. Dose adjustments may be necessary in hepatic or renal impairment. Patients should avoid alcohol and other CNS depressants during therapy. Leadpram-LS should be prescribed after a thorough clinical evaluation, considering contraindications and potential drug interactions.